(Incorporated in Delaware) We are a clinical biopharmaceutical company developing non-opioid oral therapies for acute and chronic pain. We are ready for Phase 3. We are committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Pain represents one of the largest and […]

(Incorporated in Delaware) We are a Phase 2-ready clinical biopharma company focused on developing small-molecule medicines to treat cancer. Our leading drug candidate, BH-30643, is in SOLARA, our global Phase 1/2 trial for EGFR-mutant non-small cell lung cancer (NSCLC). There is is a fragmentation of care in EGFR-mutant NSCLC because no drug is effective across […]

(Incorporated in the Cayman Islands) We are a mineral exploration and development company dedicated to developing rare earth elements in Brazil. We are a pre-revenue company. We aim to develop an alternative to Chinese supply of rare earth elements – with a focus on supplying Western markets. Our primary asset is the Itarantim Project, an […]

(Incorporated in the Cayman Islands) We are a newly established blank check company, backed by Celeres Capital of Puerto Rico. We intend to focus our search for an acquisition target on financial services and FinTech companies. We will concentrate on businesses with an aggregate enterprise value between $1.0 billion and $3.0 billion. Christopher Valentine, our […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. We intend to focus our search for an acquisition target on businesses with industry leadership and long-term revenue visibility. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region. Because of our significant ties […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company backed by Michael Klein, the former Citibank executive and dealmaker. He made his name at Citi and Salomon. He is the founder and managing partner of M. Klein and Company. This SPAC has not chosen a target industry or sector. Michael Klein […]

(Incorporated in Delaware) We are a clinical-stage biopharmaceutical company whose leading drug candidate, BHB-1893, is being evaluated to treat patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart. HCM is associated with significant morbidity, reduced quality of life, […]

(Incorporated in the Cayman Islands)  We are a Singapore-based supplier of fasteners and a distributor of solar power systems.  We supply nuts, bolts and other industrial fastener products to customers in the construction industry as well as to those in the mechanical and electrical, maritime and manufacturing sectors. We bought Lumenx Energy in June 2025. […]

(Incorporated in Delaware)  We are a Phase 1 clinical biopharmaceutical company developing next-generation biologics for immune-mediated diseases. We use our ATTOBODY platform, a biparatropic nanobody-based technology licensed from Alamar Biosciences. We have no products on the market. And we have no revenue from product sales.  Our lead drug candidate, ATTO-1310, is an ATTOBODY-based therapeutic that […]

(Incorporated in Delaware) We are a Phase 3 pharmaceutical company developing an oral medication to treat obstructive sleep apnea.  Our only clinical drug candidate, AD109, also known as Oxnimbi, is an anti-apneic neuromuscular modulator in a fixed-dose formulation to treat obstructive sleep apnea. AD109 is a combination of a novel anti-muscarinic and a selective norepinephrine […]